GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).
{iframe}https://www.globenewswire.com/news-release/2021/04/05/2204096/0/en/Emergent-BioSolutions-On-Track-with-Respect-to-COVID-19-Contractual-Commitments-Receives-Modified-Task-Order-from-the-U-S-Department-of-Health-Human-Services-to-Support-the-Opportu.html{/iframe}